New study tests if extra blood thinner can prevent second heart attacks in rare artery condition
NCT ID NCT07511257
First seen May 07, 2026 · Last updated Jun 03, 2026 · Updated 5 times
Summary
This study looks at 326 adults who recently had a heart attack and have a condition called coronary artery ectasia, where the heart arteries are abnormally widened. The goal is to see if adding a blood thinner (rivaroxaban) to one antiplatelet drug works better than the usual two antiplatelet drugs at preventing another heart attack or the need for another procedure, without causing too much bleeding. Participants will be randomly assigned to one of the two treatment groups and followed for major heart events and bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROMES (ACS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Cardiologia "Ignacio Chávez"
RECRUITINGMexico City, Tlalpan, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.